Newamsterdam Pharma Stock Analysis
NAMSW Stock | 12.51 0.24 1.96% |
NewAmsterdam Pharma is overvalued with Real Value of 10.04 and Hype Value of 12.51. The main objective of NewAmsterdam Pharma stock analysis is to determine its intrinsic value, which is an estimate of what NewAmsterdam Pharma is worth, separate from its market price. There are two main types of NewAmsterdam Pharma's stock analysis: fundamental analysis and technical analysis.
The NewAmsterdam Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. NewAmsterdam Pharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. NewAmsterdam Stock trading window is adjusted to America/New York timezone.
NewAmsterdam |
NewAmsterdam Stock Analysis Notes
The company had not issued any dividends in recent years. NewAmsterdam Pharma had 1:1 split on the 23rd of November 2022. To find out more about NewAmsterdam Pharma contact FACC Facp at 31 35 206 2971 or learn more at https://www.newamsterdampharma.com.NewAmsterdam Pharma Quarterly Total Revenue |
|
NewAmsterdam Pharma Investment Alerts
NewAmsterdam Pharma generated a negative expected return over the last 90 days | |
NewAmsterdam Pharma has high historical volatility and very poor performance | |
NewAmsterdam Pharma has high likelihood to experience some financial distress in the next 2 years | |
The company reported the revenue of 45.56 M. Net Loss for the year was (241.6 M) with profit before overhead, payroll, taxes, and interest of 45.56 M. | |
NewAmsterdam Pharma generates negative cash flow from operations | |
Latest headline from news.google.com: Newamsterdam Pharma COO Kling sells 2.36 million in stock - Investing.com |
NewAmsterdam Pharma Environmental, Social, and Governance (ESG) Scores
NewAmsterdam Pharma's ESG score is a quantitative measure that evaluates NewAmsterdam Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of NewAmsterdam Pharma's operations that may have significant financial implications and affect NewAmsterdam Pharma's stock price as well as guide investors towards more socially responsible investments.
NewAmsterdam Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.28) | (0.29) | |
Return On Capital Employed | (0.23) | (0.22) | |
Return On Assets | (0.28) | (0.29) | |
Return On Equity | (0.32) | (0.30) |
Management Efficiency
The company has return on total asset (ROA) of (0.1819) % which means that it has lost $0.1819 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.462) %, meaning that it generated substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2025. Return On Capital Employed is likely to climb to -0.22 in 2025. At this time, NewAmsterdam Pharma's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 42.3 K in 2025, whereas Intangible Assets are likely to drop slightly above 507.3 K in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 8.03 | 6.35 | |
Tangible Book Value Per Share | 8.02 | 5.65 | |
Enterprise Value Over EBITDA | (6.85) | (6.51) | |
Price Book Value Ratio | 3.20 | 3.36 | |
Enterprise Value Multiple | (6.85) | (6.51) | |
Price Fair Value | 3.20 | 3.36 | |
Enterprise Value | 1.5 B | 1.6 B |
Leadership at NewAmsterdam Pharma emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Technical Drivers
As of the 25th of March, NewAmsterdam Pharma secures the Mean Deviation of 3.33, downside deviation of 7.12, and Risk Adjusted Performance of 0.0245. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NewAmsterdam Pharma, as well as the relationship between them. Please verify NewAmsterdam Pharma jensen alpha and semi variance to decide if NewAmsterdam Pharma is priced some-what accurately, providing market reflects its recent price of 12.51 per share. Given that NewAmsterdam Pharma has jensen alpha of 0.1209, we recommend you to check NewAmsterdam Pharma's last-minute market performance to make sure the company can sustain itself at a future point.NewAmsterdam Pharma Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. NewAmsterdam Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for NewAmsterdam Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
NewAmsterdam Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NewAmsterdam Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on NewAmsterdam Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NewAmsterdam Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smither John W over two months ago Acquisition by Smither John W of 10000 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3 | ||
Louise Kooij over three months ago Disposition of 430015 shares by Louise Kooij of NewAmsterdam Pharma at 10.0 subject to Rule 16b-3 | ||
Lewis William over six months ago Insider Trading | ||
Davidson Michael H. over six months ago Acquisition by Davidson Michael H. of 10399 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3 | ||
Louise Kooij over six months ago Discretionary transaction by Louise Kooij of 213073 shares of NewAmsterdam Pharma subject to Rule 16b-3 |
NewAmsterdam Pharma Predictive Daily Indicators
NewAmsterdam Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NewAmsterdam Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Daily Balance Of Power | 9.2 T | |||
Rate Of Daily Change | 1.02 | |||
Day Median Price | 12.51 | |||
Day Typical Price | 12.51 | |||
Price Action Indicator | 0.12 | |||
Period Momentum Indicator | 0.24 | |||
Relative Strength Index | 67.15 |
NewAmsterdam Pharma Corporate Filings
F4 | 19th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10th of March 2025 Other Reports | ViewVerify | |
F4 | 6th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
28th of February 2025 Other Reports | ViewVerify | |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 31st of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
NewAmsterdam Pharma Forecast Models
NewAmsterdam Pharma's time-series forecasting models are one of many NewAmsterdam Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NewAmsterdam Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About NewAmsterdam Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how NewAmsterdam Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NewAmsterdam shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NewAmsterdam Pharma. By using and applying NewAmsterdam Stock analysis, traders can create a robust methodology for identifying NewAmsterdam entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (5.30) | (5.57) | |
Operating Profit Margin | (3.87) | (4.06) | |
Net Loss | (5.30) | (5.57) |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding NewAmsterdam Pharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
All Next | Launch Module |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.